Printer Friendly

ZENECA ANNOUNCES NEW INDICATION FOR DIPRIVAN INJECTION

 WILMINGTON, Del., Nov. 5 /PRNewswire/ -- Zeneca Inc. announced today a new indication for DIPRIVAN (propofol) Injection, its intravenous sedative-hypnotic. The product can now be used for pediatric anesthesia.
 Zeneca Inc. is a wholly owned subsidiary of the U.K.-based Zeneca Group PLC (NYSE: ZEN), a major $6 billion international bioscience company.
 Diprivan Injection is the first in a new class of intravenous sedative-hypnotic medications, and has been available in the United States since 1989 for the induction and maintenance of general anesthesia. The product also is used to sedate intubated, mechanically ventilated adults in hospital intensive care units. In 1992, U.S. sales were $100 million.
 "Approval for marketing this new indication for Diprivan Injection will increase Zeneca's position in the almost $1.2 billion U.S. anesthesia market," Keith Willard, Chairman of Zeneca Inc., said. "We are pleased that the scope of use for this important product has been expanded to include pediatric cases."
 Diprivan Injection has been demonstrated to be effective in the induction and maintenance of anesthesia in children three years of age and older. Also, comparative studies have shown that Diprivan Injection results in a reduction in the incidence of nausea and vomiting, side effects commonly seen in children who have undergone surgery using other anesthetics.
 In addition, restrictions concerning the use of Diprivan Injection in neurosurgical anesthesia have been removed. Recent studies of its use for the induction and maintenance of anesthesia in neurosurgical procedures showed the drug to be effective. Its use has also been advocated because of the rapid onset, control of anesthesia depth and rapid recovery seen in patients with whom this product is used.
 Diprivan Injection is marketed in the United States by Stuart Pharmaceuticals, an operating unit of Zeneca Pharmaceuticals Group, which has 21 compounds in development. This includes the carbapenem antibiotic MERREM (meropenem); the anti-cancer agent CASODEX (ICI 176,334); the antipsychotic SEROQUEL (ICI 204,636); ACCOLATE (ICI 204,219), for the treatment of asthma; and ARIMIDEX (D1033), for the treatment of breast cancer.
 Zeneca Pharmaceuticals Group is a business unit of Zeneca Inc., a $2.4 billion bioscience company with 7,700 employees and 49 manufacturing and research and development sites in 30 states.
 -0- 11/5/93
 /CONTACT: Pat Preston of Zeneca, 302-886-8601/
 (ZEN)


CO: Zeneca Inc. ST: Delaware IN: MTC SU:

MP -- NY017 -- 1138 11/05/93 09:58 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 5, 1993
Words:395
Previous Article:GLIMCHER REALTY TRUST INITIAL PUBLIC OFFERING OF COMMON SHARES OF BENEFICIAL INTEREST
Next Article:NEW YORK CITY MUNICIPAL WATER AUTHORITY BONDS 'A' AND 'AAA/F-1+' BY FITCH -- FITCH FINANCIAL WIRE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters